Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients: Original Article

Nephrology

Volumn 15, Issue 1, 2010, Pages 42-47

  Wu, Chih Jen ^a,b   Lin, Hsin Chang ^a   Lee, Kun Feng ^a   Chuang, Chih Kuang ^a   Chen, Yi Chou ^a   Chen, Han Hsiang ^a  

^a Taipei Taiwan   (United States)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anaemia; Erythropoietin therapy; Fe chloride; Haemodialysis; Iron sucrose; Parenteral iron formulation

Indexed keywords

ERYTHROPOIETIN; FERRIC CHLORIDE; FERRIC HYDROXIDE SUCROSE; FERRITIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; SERUM ALBUMIN; UREA;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT;

ANEMIA; CHLORIDES; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 77149130181     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01160.x     Document Type: Article

References (22)

1. Chen HH, Tarng DC, Lee KF, Wu CJ, Chen YC. Epoetin alfa and darbepoetin alfa: Effects on ventricular hypertrophy in patients with chronic kidney disease. J. Nephrol. 2008 21 : 543 549.
2. MacDougall IC. Optimizing the use of erythropoietic agents: pharmacokinetic and pharmacodynamic considerations. Nephrol. Dial. Transpl. 2002 17 (Suppl 5 66 70.
3. National Kidney Foundation. DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am. J. Kid. Dis. 2001 37 (Suppl 1 S182 238.
4. MacDougall IC, Horl WH, Jacobs C, Valderrábano F, Parrondo I, Thompson K et al. European Best Practice Guidelines 6-8: Assessing and optimizing iron stores. Nephrol. Dial. Transplant. 2000 15 (Suppl 4 20 32.
5. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am. J. Kidney Dis. 2007 47 (Suppl 3 S58 70.
6. KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am. J. Kidney Dis. 2007 50 : 471 530.
7. Coyne DW. Iron indices: What do they really mean? Kidney Int. 2006 101 : S4 8.
8. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron. Clin. Pract. 2005 100 : 55 62.
9. Jeng CC, Tian YC, Wu HH et al. Effectiveness of oral and intravenous iron therapy in hemodialysis patients. Int. J. Clin. Pract. 2008 62 : 416 422.
10. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparation. Arzneimittelforschung 1992 42 : 1439 1452.
11. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J. Am. Soc. Nephrol. 1993 4 : 1205 1213.
12. Chen HH, Tarng DC, Wu CJ, Chen YW, Ting JT. Increased erythropoietin-alpha dose when switching from subcutaneous to intravenous administration: Effect of serum albumin. Clin. Nephrol. 2008 69 : 347 353.
13. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: A combined therapeutic approach. J. Am. Soc. Nephrol. 2004 15 : S21 4.
14. Locatelli F, Aljama P, Barany P, Practice Guidelines Working Group et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 2004 19 (Suppl 2 ii1 47.
15. Wingard RL, Parker RA, Ismalil N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am. J. Kidney. Dis. 1995 25 : 433 439.
16. Tiranathanagul K, Eiam-Ong S, Tosukhowong P, Praditpornsilpa K, Tungsanga K. Oxidative stress from rapid versus slow intravenous iron replacement in hemodialysis patients. Nephrology (Carlton) 2004 9 : 217 222.
17. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am. J. Kidney. Dis. 2002 40 : 90 103.
18. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Kidney Int. 2004a 66 : 1441 1456.
19. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 2004b 65 : 2108 2112.
20. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int. 2001 60 : 2406 2411.
21. Rocha LA, Barreto DV, Barreto FC et al. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2009 4 : 105 109.
22. VanWyck DB. Lessons from NKF-DOQI: Iron management. Semin. Nephrol. 2000 20 : 330 334.